{"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"<.05","statisticalMethod":"t-test, 1 sided"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62","upperLimit":"72","value":"67"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"The percentage reduction in blood flow, blood volume,and permeability surface area of the tumor following combination therapy as determined by perfusion CT (computerized tomography) scan. The percent change represents the combined average percent change for flow, volume, and permeability together.","dispersionType":"Full Range","groups":[{"description":"Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT)\n\nBevacizumab: Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses\n\nRadiation Therapy: External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good.\n\nSurgery: Surgical resection is performed 6-7 weeks after completion of neoadjuvant therapy.","id":"OG000","title":"Bevacizumab, Radiation, and Surgery"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"3 years","title":"Average Change in Blood Flow, Blood Volume,and Permeability Surface Area","type":"SECONDARY","unitOfMeasure":"Percent Reduction"}